Prebiotic Supplements Correct Oral Probiotic Deficiency for Lasting Allergy Relief

Abstract

Allergic rhinitis has increased in the last fifty years from affecting less than a percent to more than twenty-six percent of the population. Today, more than one hundred million people in the US suffer from these seasonal or yearlong allergies. The hygiene hypothesis was proposed 30 years ago as a potential explanation for this phenomenon, and we built on that with the specific oral hygiene hypothesis. Our longitudinal pilot study suggested that oral probiotic deficiency is the cause of allergic rhinitis. This clinical trial served to verify our theory and evaluate the effectiveness of AllerPops for allergy relief. Through it, we show that AllerPops prebiotic supplements are effective in providing sustained allergy relief (p = 0.002) and can modulate oral beneficial bacteria that produce short-chain fatty acids (SCFA), such asFusobacteria, Butyrivibrio, andPeptostreptococcus. The clinical improvements correlated with changes in the relative abundance of probiotics significantly:Fusobacteria(R = 0.32, p = 0.009),Butyrivibrio(R = 0.25, p = 0.044), andPeptostreptococcus(R = 0.34, p = 0.005). These results point to the root cause of allergic rhinitis: the lack of oral probiotics that produce SCFA to pacify the immune systems. Future study of AllerPops’ theory will help society redefine the best oral hygiene practice to protect oral probiotics so that we may prevent allergic and autoimmune diseases and dental/gum infections. The trial was retrospectively registered atclinicaltrials.com, with registration numberNCT05956691, on 21/07/2023.